Free Trial

Exelixis (EXEL) News Today

$20.74
+0.25 (+1.22%)
(As of 11:22 AM ET)
Franklin Resources Inc. Has $10.42 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Franklin Resources Inc. raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 23.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 434,471 shares of the biotechnology company's stock after acquiring an additional 82,9
Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) PT at $26.13
3,061,647 Shares in Exelixis, Inc. (NASDAQ:EXEL) Purchased by Norges Bank
Norges Bank acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,061,647 shares of the biotechnology company's stock, valued at approximately $73,449,000. Norges Bank owned app
Exelixis, Inc. (NASDAQ:EXEL) Stock Position Lowered by Amalgamated Bank
Amalgamated Bank decreased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 27.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,482 shares of the biotechnology company's stock after sell
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Moderate Buy" by Brokerages
Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seventeen research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the c
Director At Exelixis Sells $576K Of Stock
Panagora Asset Management Inc. Sells 37,636 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Panagora Asset Management Inc. decreased its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 50.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,530 shares of the biotechnology company's s
Trexquant Investment LP Has $5.26 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Trexquant Investment LP trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 51.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,347 shares of the
Exelixis Resolves Two CABOMETYX Patent Disputes With Cipla
Jump Financial LLC Sells 127,788 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Jump Financial LLC trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 79.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,210 shares of the biotechnology company's stock after sellin
Exelixis, Inc. (NASDAQ:EXEL) Short Interest Up 11.0% in April
Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 9,570,000 shares, a growth of 11.0% from the April 15th total of 8,620,000 shares. Currently, 3.4% of the company's shares are short sold. Based on an average daily trading volume, of 2,380,000 shares, the short-interest ratio is presently 4.0 days.
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by BNP Paribas Financial Markets
BNP Paribas Financial Markets increased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 88.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 450,097 shares of the biotechnology company'
Exelixis (NASDAQ:EXEL) Now Covered by Analysts at Stephens
Stephens began coverage on shares of Exelixis in a report on Tuesday. They issued an "equal weight" rating and a $23.00 price target on the stock.
Seizert Capital Partners LLC Sells 43,339 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Seizert Capital Partners LLC lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 420,335 shares of the biot
Swiss National Bank Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Swiss National Bank lessened its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 564,700 shares of the biotechnology company's stock after selling 79,500 sh
LSV Asset Management Sells 879,211 Shares of Exelixis, Inc. (NASDAQ:EXEL)
LSV Asset Management trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 84.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,429 shares of the biotechnology company's stock after sel
Summit Global Investments Purchases Shares of 38,458 Exelixis, Inc. (NASDAQ:EXEL)
Summit Global Investments purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 38,458 shares of the biotechnology company's stock, valued at approximately $923
HC Wainwright Reiterates "Buy" Rating for Exelixis (NASDAQ:EXEL)
HC Wainwright reissued a "buy" rating and issued a $28.00 price objective on shares of Exelixis in a report on Friday.
William Blair Comments on Exelixis, Inc.'s Q3 2024 Earnings (NASDAQ:EXEL)
Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities research analysts at William Blair decreased their Q3 2024 EPS estimates for Exelixis in a research report issued on Wednesday, May 1st. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $0.27 per share for th
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
Exelixis (NASDAQ:EXEL) Given New $27.00 Price Target at TD Cowen
TD Cowen boosted their target price on shares of Exelixis from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Wednesday.
Exelixis (NASDAQ:EXEL) Announces Earnings Results
Exelixis (NASDAQ:EXEL - Get Free Report) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The company had revenue of $425.23 million during the quarter, compared to analyst estimates of $461.04 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. The business's revenue for the quarter was up 4.0% on a year-over-year basis.
Exelixis (NASDAQ:EXEL) Stock Rating Reaffirmed by William Blair
William Blair reissued an "outperform" rating on shares of Exelixis in a report on Wednesday.
Exelixis (NASDAQ:EXEL) Shares Gap Down on Disappointing Earnings
Exelixis (NASDAQ:EXEL) Shares Gap Down After Earnings Miss
Q1 2024 Exelixis Inc Earnings Call
Russell Investments Group Ltd. Purchases 37,438 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Russell Investments Group Ltd. raised its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,513,591 shares of the biotechnology compan
Get Exelixis News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

The only AI company to buy (Ad)

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

EXEL Media Mentions By Week

EXEL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EXEL
News Sentiment

0.94

0.80

Average
Medical
News Sentiment

EXEL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EXEL Articles
This Week

13

7

EXEL Articles
Average Week

Get Exelixis News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:EXEL) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners